WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Pharma giant ditches £1bn London research hub and says UK ‘not competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

Raccontata datelegraph.co.ukbbc.comindependent.co.uk

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
independent.co.ukStai leggendo9 mesi fa

Pharma giant ditches £1bn London research hub and says UK ‘not competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

originale
bbc.com9 mesi fa

Merck scraps £1bn expansion in the UK over lack of state investment

The firm, known as MSD in Europe, said there has been a lack of investment in life sciences.

Leggi questa versione → originale
telegraph.co.uk9 mesi fa

US drugmaker scraps plans for £1bn UK research centre

Merck criticises ‘successive UK governments’ as it cancels King’s Cross development

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 10 settembre 2025·telegraph.co.uk

    US drugmaker scraps plans for £1bn UK research centre

    Merck criticises ‘successive UK governments’ as it cancels King’s Cross development

  2. giovedì 11 settembre 2025·bbc.com

    Merck scraps £1bn expansion in the UK over lack of state investment

    The firm, known as MSD in Europe, said there has been a lack of investment in life sciences.

  3. giovedì 11 settembre 2025·independent.co.uk

    Pharma giant ditches £1bn London research hub and says UK ‘not competitive’

    Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’